Alemtuzumab demonstrates durable reduction of MRI activity over 5 years in CARE-MS II with most patients free from treatment for 4 years

作者:Traboulsee A; Cohen J A; Coles A J; Compston D A S; Fox E J; Giovannoni G; Hartung H P; Havrdova E; Selmaj K W; Margolin D H; Thangavelu K; Panzara M A; Arnold D L
来源:31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), 2015-10-07 to 2015-10-10.
  • 出版日期2015-9